Implantica AG (publ.), a medtech company at the forefront of introducing advanced technology into the body, including the unique device RefluxStop® for the treatment of acid reflux, a treatment field with 1 billion sufferers, announces RefluxStop® was a great success at the European Foregut Society (EFS) Annual Meeting in Athens last week.
The EFS Annual Meeting, brought together hundreds of Europe’s most highly esteemed acid reflux surgeons, gastroenterologists, and researchers to exchange cutting-edge knowledge on the treatment of foregut diseases. Enthusiasm about RefluxStop® was palpable throughout the Congress as attendees learned about the excellent new results of RefluxStop, addressing the root cause of GERD.
The RefluxStop Symposium, “RefluxStop for GERD: Excellent long-term outcomes” drew a full house of around 100 doctors to hear about the device’s rapidly evolving excellent long-term and real-world outcomes data. The distinguished panel of RefluxStop experts included: Prof. Sebastian Schoppmann, Dr. med. Yves Borbély, Dr. med. Moustafa Elshafei and Dr. med. Thorsten Lehmann. They provided an in-depth perspective on RefluxStop® to treat reflux disease, followed by constructive discussions with a diverse audience of European and international reflux experts.
Inventor of RefluxStop®, CEO and founder of Implantica, Dr. Peter Forsell says, “I want to sincerely thank Prof. Schoppmann and the rest of the leading RefluxStop® panelists for sharing the latest fantastic independent real-world clinical data and experience on the RefluxStop® procedure. With over 1400 patients treated across more than 50 leading reflux centers throughout Europe, while dozens more are lining up, it’s truly rewarding to hear how RefluxStop® has been embraced by hundreds of world-leading surgeons across Europe, the US, and the rest of the world.
Dr. Forsell goes on to say, “An estimated 40% of the one billion GERD sufferers do not respond to medication for the persistent and painful symptoms of the disease. RefluxStop® offers these patients, and those who eschew GERD medication for other reasons, a desperately needed new surgical option. I believe the groundbreaking RefluxStop® procedure will drive a significant paradigm shift in the overall treatment of GERD across Europe and hopefully soon in the US as we continue to advance through the final stages of our FDA approval process.”
